Literature DB >> 18725566

VEGF-D: a modifier of embryonic lymphangiogenesis.

Terhi Karpanen1, Kari Alitalo.   

Abstract

Entities:  

Year:  2008        PMID： 18725566      PMCID： PMC2518870          DOI： 10.1182/blood-2008-06-159343

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  8 in total

1.  Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice.

Authors:  T Veikkola; L Jussila; T Makinen; T Karpanen; M Jeltsch; T V Petrova; H Kubo; G Thurston; D M McDonald; M G Achen; S A Stacker; K Alitalo
Journal:  EMBO J       Date:  2001-03-15       Impact factor: 11.598

2.  VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses.

Authors:  Tuomas T Rissanen; Johanna E Markkanen; Marcin Gruchala; Tommi Heikura; Antti Puranen; Mikko I Kettunen; Ivana Kholová; Risto A Kauppinen; Marc G Achen; Steven A Stacker; Kari Alitalo; Seppo Ylä-Herttuala
Journal:  Circ Res       Date:  2003-04-24       Impact factor: 17.367

3.  VEGF-D promotes the metastatic spread of tumor cells via the lymphatics.

Authors:  S A Stacker; C Caesar; M E Baldwin; G E Thornton; R A Williams; R Prevo; D G Jackson; S Nishikawa; H Kubo; M G Achen
Journal:  Nat Med       Date:  2001-02       Impact factor: 53.440

4.  Vascular endothelial growth factor D is dispensable for development of the lymphatic system.

Authors:  Megan E Baldwin; Michael M Halford; Sally Roufail; Richard A Williams; Margaret L Hibbs; Dianne Grail; Hajime Kubo; Steven A Stacker; Marc G Achen
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

5.  Cardiovascular failure in mouse embryos deficient in VEGF receptor-3.

Authors:  D J Dumont; L Jussila; J Taipale; A Lymboussaki; T Mustonen; K Pajusola; M Breitman; K Alitalo
Journal:  Science       Date:  1998-10-30       Impact factor: 47.728

6.  Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins.

Authors:  Marika J Karkkainen; Paula Haiko; Kirsi Sainio; Juha Partanen; Jussi Taipale; Tatiana V Petrova; Michael Jeltsch; David G Jackson; Marja Talikka; Heikki Rauvala; Christer Betsholtz; Kari Alitalo
Journal:  Nat Immunol       Date:  2003-11-23       Impact factor: 25.606

7.  Distinct roles of vascular endothelial growth factor-D in lymphangiogenesis and metastasis.

Authors:  Lucie Kopfstein; Tanja Veikkola; Valentin G Djonov; Vanessa Baeriswyl; Tibor Schomber; Karin Strittmatter; Steven A Stacker; Marc G Achen; Kari Alitalo; Gerhard Christofori
Journal:  Am J Pathol       Date:  2007-04       Impact factor: 4.307

8.  Deletion of vascular endothelial growth factor C (VEGF-C) and VEGF-D is not equivalent to VEGF receptor 3 deletion in mouse embryos.

Authors:  Paula Haiko; Taija Makinen; Salla Keskitalo; Jussi Taipale; Marika J Karkkainen; Megan E Baldwin; Steven A Stacker; Marc G Achen; Kari Alitalo
Journal:  Mol Cell Biol       Date:  2008-06-02       Impact factor: 4.272
  8 in total
  3 in total

Review 1.  Novel aspects of corneal angiogenic and lymphangiogenic privilege.

Authors:  David Ellenberg; Dimitri T Azar; Joelle A Hallak; Faisal Tobaigy; Kyu Yeon Han; Sandeep Jain; Zhongjun Zhou; Jin-Hong Chang
Journal:  Prog Retin Eye Res       Date:  2010-01-25       Impact factor: 21.198

2.  Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer.

Authors:  Jill M Siegfried; Christopher T Gubish; Mary E Rothstein; Cassandra Henry; Laura P Stabile
Journal:  J Thorac Oncol       Date:  2012-03       Impact factor: 15.609

3.  Tumor lymphangiogenesis as a potential therapeutic target.

Authors:  Tam Duong; Peter Koopman; Mathias Francois
Journal:  J Oncol       Date:  2012-02-16       Impact factor: 4.375
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.